The prognostic value of the suPARnostic®ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms
Open Access
- 16 November 2007
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 7 (1), 134
- https://doi.org/10.1186/1471-2334-7-134
Abstract
High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals. Research on the clinical value of suPAR in HIV-1 infection led to the development of the suPARnostic® assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the prognostic value of the new suPARnostic® assay and 2) Determine whether polymorphisms in the active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are antiretroviral therapy (ART) naive. DNA samples were collected retrospectively from 145 Danes infected with HIV-1 with known seroconversion times. In addition, plasma was collected retrospectively from 81 of these participants for use in the suPAR analysis. Survival was analysed using Kaplan Meier analysis. Survival was strongly correlated to suPAR levels (p < 0.001). Levels at or above 6 ng/ml were associated with death in 13 of 27 patients within a two-years period; whereas only one of 54 patients with suPAR levels below 6 ng/ml died during this period. We identified two common uPAR promoter polymorphisms: a G to A transition at -118 and an A to G transition at -465 comparative to the transcription start site. These promoter transitions influenced neither suPAR levels nor patient survival. Plasma suPAR levels, as measured by the suPARnostic® assay, were strongly predictive of survival in ART-naïve HIV-1 infected patients. Furthermore, plasma suPAR levels were not influenced by uPAR promoter polymorphisms.Keywords
This publication has 28 references indexed in Scilit:
- Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South AfricaBMC Infectious Diseases, 2007
- The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortalityClinical Microbiology & Infection, 2004
- Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)Clinical and Diagnostic Laboratory Immunology, 2001
- Amino-Terminal Fragment of Urokinase-Type Plasminogen Activator Inhibits HIV-1 ReplicationBiochemical and Biophysical Research Communications, 2001
- β3A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through aPEA3/ets Transcriptional Silencing Element in the u-PAR PromoterMolecular and Cellular Biology, 2001
- A region between −141 and −61 bp containing a proximal AP‐1 is essential for constitutive expression of urokinase‐type plasminogen activator receptorEuropean Journal of Biochemistry, 1999
- Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active SrcPublished by Elsevier BV ,1999
- Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPARThe International Journal of Cell Cloning, 1997
- Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor GenePublished by Elsevier BV ,1996
- Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 SequencesJournal of Biological Chemistry, 1996